---
title: "002873.SZ (002873.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002873.SZ/news.md"
symbol: "002873.SZ"
name: "002873.SZ"
parent: "https://longbridge.com/en/quote/002873.SZ.md"
datetime: "2026-05-21T14:49:32.330Z"
locales:
  - [en](https://longbridge.com/en/quote/002873.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002873.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002873.SZ/news.md)
---

# 002873.SZ (002873.SZ) — Related News

### [Who earned the most? The ranking of net profits of traditional Chinese medicine listed companies in 2025 is revealed](https://longbridge.com/en/news/286340296.md)
*2026-05-14T01:25:12.000Z*
> Who earned the most? The ranking of net profits of traditional Chinese medicine listed companies in 2025 is revealed

### [Xintian Pharma: Has completed the sale of 2.441 million repurchased shares, with the proceeds used to replenish liquidity](https://longbridge.com/en/news/286262496.md)
*2026-05-13T12:36:15.000Z*
> Xintian Pharma announced that the company will sell repurchased shares from April 28, 2026, to July 27, 2026. As of May 

### [Xintian Pharma's controlling shareholder plans to reduce its holdings by no more than 2.9962%](https://longbridge.com/en/news/285570773.md)
*2026-05-07T14:24:07.000Z*
> Xintian Pharma's controlling shareholder, Shanghai Xintian Zhiyao Biotechnology Co., Ltd., plans to reduce its holdings 

### [Xintian Pharma: First sale of repurchased shares, 789,800 shares](https://longbridge.com/en/news/285535217.md)
*2026-05-07T11:02:19.000Z*
> Xintian Pharma announced that on May 7, 2026, the company will first sell 789,800 repurchased shares through centralized

### [Xintian Pharma released its first-quarter performance, with a net profit attributable to the parent company of 3.4952 million yuan, a decrease of 16.53%](https://longbridge.com/en/news/284609356.md)
*2026-04-29T15:58:04.000Z*
> Xintian Pharma released its first quarter report for 2026, with operating revenue of 179 million yuan, a year-on-year de

### [Xintian Pharma: Subsidiary obtains two invention patents](https://longbridge.com/en/news/281996849.md)
*2026-04-08T07:51:43.000Z*
> Xintian Pharma announced that its wholly-owned subsidiary Shanghai ShuoFang Pharmaceutical Technology Co., Ltd. recently

### [Xintian Pharma: Plans to sell no more than 1% of repurchased shares](https://longbridge.com/en/news/281524622.md)
*2026-04-02T12:34:02.000Z*
> Xintian Pharma announced that the company plans to hold a board meeting on April 2, 2026, to review the proposal to sell

### [Xintian Pharma: Net profit of 9.1115 million yuan in 2025, a year-on-year decrease of 82.59%](https://longbridge.com/en/news/281006095.md)
*2026-03-30T11:07:26.000Z*
> Sina Finance reported on March 30th that Xintian Pharma announced that its operating revenue in 2025 is expected to be 7

### [Xintian Pharma: Transferred 4 drug marketing licenses and related production technologies to Xin'an Tang Group](https://longbridge.com/en/news/273971850.md)
*2026-01-28T10:11:00.000Z*
> Xintian Pharma announced that the company held a board meeting on January 27, 2026, and approved the proposal on the ext